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doi:10.1016/j.jmii.2011.01.005Background: Toxoplasmosis is a disease, which can cause severe congenital infection and is nor-
mally diagnosed by the detection of Toxoplasma gondii (T gondii)-specific antibodies in the
serum of infected patients. Several different tests allow to distinguish recent from past infec-
tions and to quantify anti-T gondii-specific IgG, and the results can be used as markers for
a chronic or recently seroconverted toxoplasma.
Methods: In the present study, the recent Cobas 6000 Toxo IgG assay (Roche Diagnostics, India-
napolis, IN, USA) for the serological diagnosis of toxoplasmosis was compared with the Axsym
Toxo IgGassay (Abbott Laboratories, DiagnosticsDivision, Abbott Park, IL,USA)employingapanel
of negative, low- or high-reactive serum samples that were selected after routine screening in
a laboratory of clinical analyses.
Results: The overall agreement between two methods was 99% (rZ 0.99, p< 0.001). Of 91
analyzed samples, only one presented discrepant result, being positive in the Cobas 6000 Toxo
IgG assay and negative in the Axsym Toxo IgG assay. By using an immunofluorescent assay as
a confirmation test, this positive result was assayed to be negative.
Conclusions: Both assays performed in each analyzer were proven to be fast and fully automated
procedures for reproducible measurement of IgG antibodies to T gondii. The new method, used
for the determination of anti-T gondii IgG antibodies, should be evaluatedwith a further analysis
with increased number of serum samples to get a broad performance of this newer test.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Biochemistry, Clinical Laboratory, Memorial Hospital, Piyalepasa Bulvari 34385, Istanbul, Turkey.
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Toxoplasmosis, a ubiquitous protozoal disease, is caused by
an intracellular parasite, Toxoplasma gondii (T gondii). This
is mainly acquired by ingestion of food or water that is
contaminated by mature oocysts shed by cats or by under-
cooked meat containing tissue cysts.1 Primarily, acute
toxoplasmosis, which is mostly mild or asymptomatic, is
generally benign in healthy people. However, it can be
serious in the context of immunodeficiency, especially in the
case of AIDS and bone marrow or heart transplant patients
or in children infected in utero. However, reactivation of
a latent Toxoplasma as a result of immunosuppression is
frequently associated with meningoencephalitis.2,3 Primary
maternal toxoplasma occurs during pregnancy may lead to
severe damage of the fetus as the parasite can transmit
across the placenta. Most infants with congenital infection
do not present any clinical symptoms at birth but may
develop severe sequelae later in life, such as mental and
psychomotor retardation, chorioretinitis, and hear loss.4 The
fetal rate increases with gestational age. However, the risk
of severe clinical manifestations is higher in case of early
maternal infection.4e6 Early drug therapy in acute toxo-
plasmosis during pregnancy can prevent congenital damage
or ameliorate the severity of clinical manifestations.4e6
A wide range of assays for the diagnosis of toxoplasma is
available on the commercial market, and many are used in
laboratories throughout Turkey. The assays vary in their
format and in their ability to detect different types of
antibody classes (some IgG specifically, others all antibody
classes). This feature may lead to variation in the perfor-
mance of the assays and makes the choice of assay for
individual diagnostic laboratories complex. In addition,
laboratories should use evidence-based medicine in their
decision-making process.
In recent years, clinical laboratories have seen a drastic
increase in demand for automated detection of antibodies
to T gondii by assays based on immunoassay technology.7,8
The determination of IgG antibodies with a significant rise
titers to T gondii is used to assess the serological status to
toxoplasmosis and indicate a chronic or recently sero-
converted toxoplasma. In the present study, the perfor-
mance characteristics of the new Toxo IgG antibody assay
on the Cobas 6000 analyzer (Roche Diagnostics, Indian-
apolis, IN, USA) was compared with those of Axsym Toxo IgG
(Abbott Laboratories, Diagnostics Division, Abbott Park, IL,
USA) antibody assay on the Axsym automated analyzer
systems with respect to reproducibility and correlation. We
review the performance of these assays and offer the
importance of the results in patient counseling for
specialist and nonspecialist laboratories.
Methods
The study related to 91 sera. They were obtained from the
routine activity of the Central Clinical Laboratory at
Memorial Hospital for the period MarcheApril, 2007 and
consisted of sera from pregnant women, newborns, immu-
nocompetent, and immunocompromised patients. They
included negative samples as well as samples with low,
medium, and high levels of IgG antibodies to T gondiidetected by Toxo IgG Axsym. Cobas 6000 Toxo IgG, mar-
keted by Roche Diagnostics, is a relatively new product but
increasingly being used in Europe. The sera were stored at
20C until testing. For each serum tested by Axsym Toxo
IgG before, the biological interpretation (presence or
absence of IgG) considered results were obtained with
Cobas 6000 Toxo IgG.
Cobas 6000 Toxo IgG antibody immunoassay
Ten microliter sample, a biotinylated recombinant T gon-
dii-specific antigen and T gondii-specific recombinant
antigen labeled with a ruthenium complex form a sandwich
complex. After addition of streptavidin-coated micropar-
ticles, the complex bind to the solid phase via interaction
of biotin and streptavidin. The reaction mixture is aspi-
rated into the measuring cell where the microparticles are
magnetically captured onto the surface of the electrode.
Unbound substances are then removed with ProCell.
Application of a voltage to the electrode then induces
chemiluminescent emission, which is measured by a pho-
tomultiplier. Results are expressed as international units
per milliliter in the IgG assay. Interpretation of IgG results
was based on the manufacturer’s criteria as follows:
3.0 IU/mL, positive for IgG antibodies; 1.0 to <3.0 IU/
mL, equivocal result; and <1.0 IU/mL, negative for IgG
antibodies.
Abbott Axsym Toxo IgG antibody immunoassay
The Abbott Axsym uses an automated system, which is
based on microparticle enzyme immunoassay technology to
detect antibodies to T gondii. After manual pipetting of
sera into individual reaction cells, all subsequent steps are
automated. The instrument delivers the sample and diluent
buffers to the predilution well of the reaction cell. T gon-
dii-coated microparticles and diluted sample are added to
the incubation well, where the T gondii antibody binds to
the T gondii-coated microparticles, forming an antigen-
antibody complex. A diluted aliquot of this antigen-anti-
body complex is transferred to the glass fiber matrix, which
irreversibly binds the microparticles. After washing the
matrix to remove unbound materials, class-specific anti-
human IgG-alkaline phosphatase conjugate is dispensed
onto the matrix, where it binds to the antigen-antibody
complex. The matrix is again washed to remove unbound
materials; this is followed by addition of the substrate, 4-
methylumbelliferyl phosphate. The resulting fluorescent
product is measured by the microparticle enzyme immu-
noassay optical assembly. The intensity of the fluorescence
is proportional to the quantity of toxoplasma antibodies.
Results are expressed as international units per milliliter.
Interpretation of IgG results was based on the manufac-
turer’s criteria as follows: >3.0 IU/mL, positive for IgG
antibodies; 2.0e3.0 IU/mL, equivocal result; and <2.0 IU/
mL, negative for IgG antibodies.
System precisions as indicated by the coefficient of
variation (CV%) were evaluated by intra- and interassay
testing of negative and positive controls in each assay.
Intra-assay precision was determined by running three
consecutive runs of each negative and positive control for
Toxoplasma gondii, IgG detection 23IgG antibodies. Interassay precision was determined by
testing one negative and one positive control, each in
duplicate, for 10 days.
Results for sera with discrepant results for IgG antibodies
were then verified by an immunofluorescent assay (Panbio,
Inc., Columbia, MD, USA). System precisions as indicated by
the CV% were evaluated by intra- and interassay testing of
negative and positive controls in each assay.
Statistics
The CV% was used to determine intra- and interassay
precision and reproducibility. CV% was used to determine
the statistical agreement between the different tests using
the McNemar test. Overall agreement was defined as the
percentage of specimens that were positive or negative in
the Axsym assay and gave the same positivity and negativity
in the Cobas 6000 assay.9
Results
The within-run and between-run reproducibility rates,
calculated as the CV%, were between nonapplicable and
2.8% for serum samples tested by Axsym Toxo IgG and
between 1.6% and 3.0% for those tested with the Cobas
6000 Toxo IgG assay. The results are presented in Table 1.
The within-run reproducibility rates of negative and posi-
tive controls of each were below 0.1 for Axsym Toxo IgG and
calculated CV% value was shown as nonapplicable. This
indicated that Axsym Toxo IgG assay has a higher degree of
assay and/or technical precision rather than Cobas 6000
Toxo IgG assay. The assays proved to be highly reproducible
both within runs and between runs. After successfully
completing reproducibility testing, evaluation of the clin-
ical specimens began.
In the study comparing the Cobas 6000 and Axsym Toxo
IgG assays, 17 sera of 91 routine laboratory sera were
considered as positive; and for anti-T gondii IgG, 73 as
negative and 1 as discordant. Figures 1 and 2 show a graphic
representation of the reactivity variations for negative and
positive samples.
Table 1 shows the results of 17 serum samples that were
positive in both automated assays. The reactivity indices
showed that the reactivity was significantly higher in the
Cobas 6000 when compared with the Axsym. The average
reactivity of the Cobas 6000 assay was 302.4 UI/mL, whereas
the Axsymassay showed an average reactivity of 54.5 UI/mL.Table 1 Summary of precision data for Axsym and Cobas 6000
Axsym Toxo IgG
Serum sample Mean
(IU/mL)
Within-run
CV (nZ 6)a
Betwe
CV (n
Negative control 0.1c NA 1.8
Positive control 19.3c NA 2.8
a Three replicates per run.
b Two samples per run for 10 days.
c p< 0.0001.
CVZ coefficient of variation; NAZ nonapplicable.The reproducibility studies were also the same as the mean
valueofCobas 6000. Toxo IgGwas higher thanAxsymToxo IgG
(48.6 IU/mL vs. 19.3 IU/mL for positive controls and
0.767 IU/mL vs. 0.1 IU/mL for negative controls).
Only one serum sample has a discrepant result. It was
Cobas 6000 Toxo IgG assay positive (titer, 41 IU/mL) but
Axsym Toxo IgG assay negative (titer, 0 IU/mL). This sample
was retested in each analyzer and the same results were
obtained. The same serum was negative by indirect fluo-
rescent antibody (IFA) test. The overall agreement between
two methods was 99% (rZ 0.99, p< 0.001). These results
indicate a close quantitative correlation between Axsym
Toxo IgG assay and the Cobas 6000 Toxo IgG assay. Table 2
illustrates the comparative performances of the Cobas 6000
and Axsym assays.Discussion
The detection of anti-T gondii IgG is considered to be
a marker for a chronic or recently seroconverted toxo-
plasma and is very important as a reference for clinical and
epidemiological patient management and counseling.
Today, in the case of toxoplasmosis, new diagnostic
parameters, such as IgG avidity, are assessed to identify the
most likely time of and to allow the physician to better
evaluate the clinical management of each patient.10e12 In
many health care services, the detection of anti-T gondii-
specific IgG implicates that the patient is considered pro-
tected against the disease in case of a new contact with the
parasite. Consequently, the performance of assays that
detect specific IgG is of vital importance, and several
investigations on this diagnostic approach are underway.
A number of techniques have been applied to detect IgG
antibodies in patients with toxoplasma, including the dye
test,13 direct agglutination assay,14,15 IFA,16 and ELISA.17
Because of the practicability, rapidity, and reliability
of immunoassays, automated detection of antibodies to
T gondii on the basis of immunoassay technology has gained
widespread use over the past few years in clinical labora-
tories.8 Among these tools, the automated and standard-
ized assay for anti-T gondii-specific IgG detection newly
developed by Roche Diagnostics occupies an important
position.
Evaluation of clinical specimens for IgG-specific anti-
bodies to T gondii was performed by using the Cobas 6000
and Axsym assays. The Cobas 6000 is a new product but is
increasingly being used in Turkey. The Axsym Toxo IgG assayToxo IgG assays
Cobas 6000 Toxo IgG
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Figure 1. Positive reactivity of serum samples in each system.
24 N. Tekkesin et al.has been used throughout Turkey for many years. The Cobas
6000 assay had not previously been evaluated with the
Axsym assay. We review the performance of these assays
and offer the best advice for specialist and nonspecialist
laboratories in Turkey. Detection and measurement of IgG-
specific antibodies is rarely problematic, and good sensi-
tivity and specificity have been achieved by a variety of
methods.18e22 A clinical laboratory must not rely on the
manufacturer to ensure a continuing supply of reagents but
must institute its own verification procedures for each kit
as well as performing an initial evaluation.23 Kit inserts
have demonstrated a sensitivity of 99.7% and specificity of
99.1% for Abbott Axsym and 99.5% and 98.8%, respectively
for Cobas 6000. As we could not have any chance to verify
the other samples qualitatively by IFA, it would not be true
to calculate the sensitivities and specialties of both assays.
Further analysis should be organized for this purpose.
Overall, the agreement between two assays was found very
high (rZ 0.99, p< 0.001).Sera negativity 
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Figure 2. Negative reactivity ofPrecision rates are generally presented as the assay
precision rate but actually reflect the combination of the
technologist’s precision and that of the assay. With both
assays, the addition of a measured amount of undiluted
patient serum to the test cassette is the only manual
procedure required. One would therefore expect improved
precision with the automated assays as opposed to the
manual assays. The Cobas 6000 Toxo IgG is proved to be
highly reproducible both within runs and between runs,
with a higher detection titer than Axsym Toxo IgG in posi-
tive and negative reactive samples. Low titers of anti-T
gondii IgG antibodies often maintain ambiguity on the
protective immunity notion. In this regard, the high reac-
tivity performance of Cobas 6000 Toxo IgG assay might have
an advantage.
In this study, the material analyzed consisted of both
negative and positive IgG serum samples and included
a large range of positive IgG titers. The different IgG titers
obtained from the same serum samples with different testsfor Toxo G
0
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serum samples in each system.
Table 2 Comparison of performances of Axsym and Cobas 6000 Toxo IgG assaysa
No. of serum samples (nZ 91) No. of serum samples with indicated results % Agreement
Axsym Toxo IgG negative Axsym Toxo IgG positive
Cobas 6000 negative 73 0 99a
Cobas 6000 positive 1 17
a rZ 0.99 between two assays (p< 0.001).
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according to the serological methods. It is well established
that identical titers cannot be obtained with commercial
kits using different antigenic extracts from T gondii.24 In
studies that compare the performances of various methods
to detect IgG antibodies to T gondii, it has been shown that
no method is perfect.25e27 Such studies have shown that
certain sera yield discordant results. In our study, the
results indicate close quantitative agreement between
Axsym Toxo IgG assay and the Cobas 6000 Toxo IgG assay.
Compared with Axsym Toxo IgG assay, Cobas 6000 showed
only one discrepant result, confirmed by IgG-specific IFA
test. The same sample was analyzed for the second time by
another Cobas 6000 Toxo IgG kit perhaps resulting vari-
ability among kit lots. But, again it was positive, probably
because of a cross-reactivity, an undefined interference or
may be explained by differences in the sensitivity and in
the kinetics of these two methods. This suggests that the
result obtained for this discrepant serum by the Cobas 6000
Toxo IgG assay is false-positive.
For this study, an immunofluorescent assay for T gondii
IgG antibody was designated as the reference assay for the
determination of discrepancy reason because of the depth
of experience and data accumulated with this assay.28 Sera
collected during various stages of and convalescence often
could give different results because methods have different
sensitivities, measure different immunoglobulin classes
of antibodies, or measure antibodies to different viral
components.29 One of the reasons for these test differ-
ences may be the different antigens coated on the solid
phase of each assay and the resulting ability of each assay
to detect these immunoglobulin classes and viral compo-
nents. Specimens that yielded discordant test results
following evaluation by Cobas 6000 may be explained by
such differences in solid-phase coating. The remaining
discrepant Toxoplasma IgG specimen had insufficient
volume for further testing. Otherwise, it was evaluated
further by the Sabin-Feldman dye test 13 that would be the
second step confirmatory analysis. The authors determined
that the dye test should be retained as a reference test and
as an additional confirmatory test for the validation of
commercial kits.30 As the results were obtained using
retrospective samples, we have no chance to take
a subsequent sample afterward. In a practical way, when
positive results are obtained with the two methods,
a subsequent serum sample taken 3 weeks later is tested,
so as to verify the presence of a positive and stable titer of
anti-T gondii IgG antibodies. In fact, the host defense
mechanisms against Toxoplasma depend mainly on cell-
mediated immunity.31 On the other hand, in case of
discordant results, it is advisable to consider the patient asnonimmune, thereby necessitating a serological follow-up
during the pregnancy.
As we could not have any chance to verify the other
samples qualitatively by IFA, it would not be true to
calculate the sensitivities and specialties of both assays.
Besides, Cimon et al.32 found a lower sensitivity of IFA
compared with Toxo IgG Axsym and may be related to the
lack of antigen affinity purification and the sometimes-
delicate microscope reading at the threshold dilution. Also,
serological methods are often not sufficient in the follow-
up of immunocompromised patients.33 For Toxo IgG Axsym
and IFA, Roux-Buisson et al.34 found false-negative and
false-positive results in immunocompromised patients. In
practice, IFA should be used in a laboratory in combination
with another method with different antibody kinetics in
necessity.
The knowledge of the specificity and sensitivity of test
performance is fundamental for a physician so that he or
she can make correct decisions and patient counseling,
especially during pregnancy. A further analysis with a much
larger sample of specimens should be done to evaluate
a broad performance of this newer test. However, the
results of this study should be taken into consideration
when interpreting a positive result obtained with Cobas
6000 Toxo IgG kit.
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